Standing Desks May Not Be The Silver Bullet We Thought

You might want to sit down for this.

Health & Lifestyle
212

Listen to article (english)

Translate to Spanish or other 102 languages!

Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you. Image for illustration purposes
Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you. Image for illustration purposes

Medical News Today

- Advertisement -

If you, like me, have invested in a standing desk, new research from the University of Sydney may challenge an established idea about workplace wellness. After analyzing data from 83,000 adults, researchers uncovered something surprising: Standing more doesn’t improve heart health compared to sitting, and after as little as 2 hours, it might actually harm you.

Follow the link below to read the full story on Medical News Today:

https://www.medicalnewstoday.com/articles/can-standing-too-much-harmful-heart-health-sitting?utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=sundaysupplement&utm_content=2024-10-27&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
New Stroke Prevention Guidelines Highlight Lifestyle Changes
Next article
A Journey into Ultrasound Technology

More Articles

STHS Behavioral’s Summer Mental Health Tips for Kids

STHS Behavioral urges families to prioritize emotional well-being by maintaining routines, encouraging social connections and fostering growth beyond the classroom.

New Insight Into the Iron-Retention Strategies of Colorectal Cancer Cells

Mega Doctor News by Michigan Medicine - University of Michigan Newswise — ANN ARBOR, Michigan...

Study: Weight Loss Drugs Cut Risk of Four Cancers by Half or More

Medical News Today The use of glucagon-like peptide-1 (GLP-1) receptor agonistTrusted Source medications continues...

FDA Approves Expanded Use of Kidney Cancer Treatment Rooted in UTSW Discovery

Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier stage kidney cancers in combination with an immunotherapy drug. This move marks the latest expansion of belzutifan’s indications after it was originally approved in 2021.
- Advertisement -